Head to Head Analysis: Oncobiologics (NASDAQ:OTLK) vs. Equillium (NASDAQ:EQ)

Equillium (NASDAQ:EQ) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Profitability

This table compares Equillium and Oncobiologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Oncobiologics	N/A	N/A	-254.82%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Equillium and Oncobiologics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1	1	7	2	2.91
Oncobiologics	1	2	2	0	2.20

Equillium presently has a consensus target price of $7.57, indicating a potential upside of 473.59%. Oncobiologics has a consensus target price of $5.20, indicating a potential upside of 1,081.55%. Given Oncobiologics’ higher possible upside, analysts plainly believe Oncobiologics is more favorable than Equillium.

Volatility and Risk

Equillium has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.

Earnings and Valuation

This table compares Equillium and Oncobiologics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10 million	2.04	-$22.40 million	($0.20)	-6.60
Oncobiologics	$1.35 million	79.36	-$62.42 million	($0.77)	-0.57

Equillium has higher revenue and earnings than Oncobiologics. Equillium is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

27.1% of Equillium shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Equillium beats Oncobiologics on 10 of the 13 factors compared between the two stocks.

About Equillium

Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company seeks to address immune-system dysregulation by developing treatments that selectively modulate immune-cell activity rather than broadly suppressing the immune system. Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, a protein involved in the activation and trafficking of certain T cells. The company has evaluated itolizumab in conditions including acute graft-versus-host disease and lupus nephritis.

About Oncobiologics

Oncobiologics, now known as Outlook Therapeutics, Inc. (NASDAQ: OTLK), is a biopharmaceutical company focused on developing and commercializing ophthalmic therapies for retinal diseases. The company was established as Oncobiologics and later changed its name to Outlook Therapeutics to reflect its emphasis on eye-care products. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab designed for intravitreal use. The therapy has been studied for vascular retinal conditions, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.